Thailand Clinical Trial Approval: Thai FDA + EC

Thailand’s clinical trial approval pathway runs on two parallel tracks that must both clear before a trial can enroll subjects: authorization from the Thai Food and Drug Administration (Thai FDA), operating under the Ministry of Public Health, and approval from a Thai FDA-recognized Ethics Committee (EC). Unlike jurisdictions where the drug regulator and the ethics body are fully independent, Thailand’s system links them directly: the Thai FDA will not issue an import license or a domestic-manufacture permit for investigational product without documented proof that a recognized EC has already reviewed and approved the protocol at each trial site. This guide walks through both tracks, who runs them, and how they fit together for research administrators and sponsors planning a trial in Thailand.

Who regulates clinical trials in Thailand

The Thai FDA is Thailand’s national regulator for pharmaceuticals, medical devices, and — through its authority over drug imports and production — clinical research involving investigational drugs. Its authority derives from the Drug Act B.E. 2510 (1967) and subsequent notifications, which give the Thai FDA control over importing drugs for research purposes and producing sample drugs for human studies. Because Thai law does not have a single dedicated “clinical trials act” comparable to the EU Clinical Trials Regulation, the Thai FDA regulates trials indirectly: a sponsor cannot legally bring an investigational drug into Thailand, or manufacture a sample product domestically for a study, without Thai FDA authorization — and the Thai FDA will not grant that authorization without prior EC approval.

Within the Thai FDA, applications for investigational drug import and sample-production permissions are handled by the agency’s medicines-regulation function, submitted through the Thai FDA’s centralized application service. The Thai FDA’s review scope covers Phase I through Phase IV studies of new drugs, unregistered drugs, registered drugs being studied for a new dose or a new indication, and locally produced drugs requiring efficacy testing.

The Ethics Committee requirement

Every clinical trial conducted in Thailand needs ethics approval from an EC that the Thai FDA formally recognizes, and that approval must be obtained per trial site before the Thai FDA will process the corresponding import/production application. Two Bangkok-based bodies function as the most commonly used central ECs for trials without an appropriate institutional EC of their own:

Ethical Review Committee for Research in Human Subjects, Ministry of Public Health (ECMOPH) — the ministry’s own central ethics review body.
Central Research Ethics Committee (CREC) — established in 2014 through a collaboration of Thai public and private research institutions, created specifically to add central-review capacity as trial volume in Thailand grew.

Beyond these two, the Thai FDA maintains a wider roster of recognized institutional and hospital-based ECs; sponsors and CROs should confirm current recognition status directly with the Thai FDA or the EC in question before relying on it, since recognition lists are maintained and updated by the regulator rather than fixed in statute. Thai EC composition requirements follow the pattern common to ICH-region ethics bodies: a mix of medical/scientific and non-scientific members, including at least one person independent of the institution, with guidance calling for a meaningful proportion of members trained specifically in research ethics.

All Thai clinical trials are expected to be conducted per ICH E6 Good Clinical Practice (GCP) and Thailand’s own ethical guidelines for research involving human subjects — the same GCP framework referenced throughout CASRAI’s Good Clinical Practice and ICH E6(R2) content, not a Thailand-specific alternative standard.

How the two tracks fit together

In practice, the pathway runs roughly as follows, though sponsors should confirm current procedural detail directly with the Thai FDA and their chosen EC before finalizing a submission timeline:

Protocol and EC submission. The sponsor (directly or via a local CRO) submits the protocol, investigator’s brochure, informed consent materials, and supporting documentation to the EC at each participating site, or to a recognized central EC such as ECMOPH or CREC.
EC review. The EC reviews the scientific and ethical merit of the protocol, including risk-benefit balance, informed consent process, and investigator qualifications, following its own standard review cycle. Some central ECs offer an expedited track for qualifying amendments or lower-risk protocols in addition to full-board review; cycle length varies by committee and protocol type and should be confirmed with the specific EC rather than assumed.
Thai FDA application. In parallel with, or following, EC review, the sponsor applies to the Thai FDA for an investigational drug import license or a sample-drug production permit, submitting the application through the agency’s centralized service.
Proof of EC approval required for Thai FDA sign-off. The Thai FDA will not finalize the import/production authorization until it has documented evidence of EC approval for that trial site. This is the structural link between the two tracks: EC approval is a gating requirement for Thai FDA authorization, not a parallel, independent approval that a sponsor can substitute for it.
Site initiation. Once both the EC approval and the Thai FDA authorization are in hand, the site can proceed to initiation and enrollment, subject to any site-specific institutional requirements.

Sponsors should treat any specific fee schedule or day-count timeline cited in third-party regulatory summaries as indicative rather than current-and-binding — Thai FDA and EC fee schedules and review timeframes are administrative details that change periodically, and the authoritative figures are whatever the Thai FDA and the specific EC publish at the time of submission, not what any secondary source reported previously.

Practical considerations for research administrators

Import licensing has a validity window. A drug import license, once granted, is understood to remain valid for a period of years rather than requiring renewal per shipment or per study visit — confirm the current validity period directly with the Thai FDA when planning a multi-year study, since this is exactly the kind of administrative detail that shifts with regulatory updates.
Central EC vs. institutional EC. Multi-site sponsors without an existing relationship at every site often route through a recognized central EC such as CREC or ECMOPH rather than negotiating separate institutional EC review at each hospital, which can shorten start-up time for larger trials.
Both approvals are prerequisites, not formalities. Because the Thai FDA gates its own authorization on EC sign-off, a sponsor cannot use a favorable Thai FDA pre-review to skip or shortcut EC review, or vice versa — both must be secured, and secured for the correct trial site(s), before enrollment.
GCP compliance is expected throughout, not just at approval. ICH E6 GCP obligations — informed consent documentation, monitoring, adverse event reporting, essential document retention — apply for the life of the trial, not only at the initial approval stage.

How Thailand compares to other Southeast Asian pathways

Thailand’s dual-track structure — a drug regulator that gates its own authorization on ethics-committee sign-off — has direct analogues elsewhere in the region, though the specific regulator names, forms, and timelines differ country to country. CASRAI covers several of these in companion guides:

For the broader distinction this guide relies on throughout, see CASRAI’s IRB vs. Ethics Committee comparison and the Investigational New Drug (IND) dictionary entry for the equivalent US concept that Thailand’s import-license/production-permit mechanism parallels.

Frequently asked questions

Does Thailand have a single national ethics committee for all trials?

No. Thailand does not operate one mandatory national EC that reviews every trial. Instead, sponsors use either an institutional EC at the trial site or one of the Thai FDA-recognized central ECs, most commonly ECMOPH or CREC, which exist specifically to provide central review capacity where a site-level EC isn’t available or practical.

Can a trial start in Thailand with EC approval but before Thai FDA authorization, or vice versa?

No. Enrollment requires both: the Thai FDA will not finalize the import/production authorization without documented EC approval for that site, and EC approval alone does not authorize importing or producing investigational product. Both approvals must be in place before the site can initiate.

Is ICH GCP mandatory for trials conducted in Thailand?

Yes — Thai regulatory and ethical guidance for clinical research expects trials to follow ICH E6 Good Clinical Practice alongside Thailand’s own ethical standards for human subjects research, consistent with Thailand’s participation in the broader ICH-aligned regulatory environment used across much of Southeast Asia.

Who should a sponsor contact to confirm current fees and timelines?

The Thai FDA directly, and the specific EC being used (e.g., CREC or ECMOPH, or the relevant institutional EC), since both bodies set and periodically update their own fee schedules and review timeframes — third-party summaries should be treated as a starting reference, not the current authoritative figure.